PepEvolutionMazdutide
China-approved dual GLP-1/glucagon agonist (NMPA 2025) — robust GLORY program data, very limited Western sourcing.
Verdict — C · Emerging / Mixed
NMPA-approved with strong phase-3 data, but Western availability is near-zero and any gray-market material should be treated with high skepticism. A China-validated compound with limited reach outside that market today.
Overview
Mazdutide (IBI362, Innovent Biologics) is a dual GLP-1/glucagon receptor agonist that received NMPA approval in China in 2025 for weight management following the GLORY phase-3 program. Phase-3 data show approximately 16-18% weight loss. Western regulatory approval has not been sought; sourcing outside mainland China is essentially unverified.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.